Lifeboat Foundation

Key Takeaways Key Takeaways.

Immune-focused drugs such as nivolumab and ipilimumab have greatly improved the survival of people battling advanced melanomasA new trial finds a combo of these drugs can help people survive at least six years, on average, and maybe moreNo new ‘safety signals’ from use of the drugs were noted over the decade-long trial.